Wedbush has increased its price target for Tyra Bioscience to $53 from $37, while maintaining an “Outperform” rating on the stock. This adjustment reflects a more optimistic outlook by the analyst firm for the biotechnology company. The article also lists various other analyst actions and company news related to Tyra Biosciences over recent months.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Wedbush Raises Price Target on Tyra Bioscience to $53 From $37, Keeps Outperform Rating
Wedbush has increased its price target for Tyra Bioscience to $53 from $37, while maintaining an “Outperform” rating on the stock. This adjustment reflects a more optimistic outlook by the analyst firm for the biotechnology company. The article also lists various other analyst actions and company news related to Tyra Biosciences over recent months.